Curatis Announces Formation of Distinguished Advisory Board

Liestal, Switzerland, 11 March 2025: Curatis Holding AG (SIX: CURN) announces the formation of a distinguished Scientific and Medical Advisory Board to support the development of its pipeline projects.

The Advisory Board comprises leading experts in oncology, neurology, drug development, and biochemistry: Stewart Goldman MD (Pediatric Oncology), Prof. Andreas Gantenbein (Neurology & Headache), Dr. Anthony Man (Drug Development), and Prof. Arnim Pause (Biochemistry).